C4 Therapeutics, Inc.
CCCC
$4.26
-$0.14-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.86M | 35.95M | 30.11M | 34.24M | 39.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.86M | 35.95M | 30.11M | 34.24M | 39.78M |
| Cost of Revenue | -16.93M | -15.51M | -10.81M | -4.96M | -7.41M |
| Gross Profit | 51.79M | 51.45M | 40.92M | 39.20M | 47.19M |
| SG&A Expenses | 36.20M | 36.20M | 37.39M | 40.24M | 41.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.97M | 140.44M | 149.16M | 157.86M | 156.34M |
| Operating Income | -103.11M | -104.49M | -119.05M | -123.62M | -116.56M |
| Income Before Tax | -103.68M | -104.87M | -118.95M | -111.45M | -103.15M |
| Income Tax Expenses | 121.00K | 121.00K | 131.00K | 131.00K | 131.00K |
| Earnings from Continuing Operations | -103.80 | -104.99 | -119.08 | -111.58 | -103.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.80M | -104.99M | -119.08M | -111.58M | -103.28M |
| EBIT | -103.11M | -104.49M | -119.05M | -123.62M | -116.56M |
| EBITDA | -101.20M | -102.53M | -117.04M | -121.63M | -114.73M |
| EPS Basic | -1.18 | -1.36 | -1.67 | -1.58 | -1.47 |
| Normalized Basic EPS | -0.66 | -0.77 | -0.97 | -1.01 | -0.96 |
| EPS Diluted | -1.18 | -1.36 | -1.67 | -1.58 | -1.47 |
| Normalized Diluted EPS | -0.66 | -0.77 | -0.97 | -1.01 | -0.96 |
| Average Basic Shares Outstanding | 386.43M | 331.19M | 285.01M | 282.07M | 279.88M |
| Average Diluted Shares Outstanding | 386.43M | 331.19M | 285.01M | 282.07M | 279.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |